Pan ‑immune‑inflammation value as a novel prognostic biomarker in nasopharyngeal carcinoma

In conclusion, the PIV was a powerful predictor of survival outcomes and outperformed the SII in patients with NPC treated with chemoradiotherapy. Prospective validation of the PIV should be performed to better stratify radical treatment of patients with NPC.PMID:38646495 | PMC:PMC11027095 | DOI:10.3892/ol.2024.14385

Source: Oncology Letters - April 22, 2024 Category: Cancer & Oncology Authors: Zhen Su Jie Tang Yan He Wei Hua Zeng Qian Yu Xiao Long Cao Guo Rong Zou Source Type: research